

Development of Long-Acting FGF21M5-Based Fusion Proteins as Therapeutic Lead for MASH Treatment

Ewha University-Industry Collaboration Foundation



EWHA WOMANS
UNIVERSITY

METABOLIC	Lead
Product Type	rProtein
Indication	Metabolic dysfunction-associated steatohepatitis (MASH)
Target	FGFR/KLB
MoA(Mechanism of Action)	FGF21 analog-mediated activation of FGFR1c/ β -Klotho(KLB) signaling to improve hepatic steatosis, inflammation, and fibrosis in MASH
Competitiveness	FGF21M5: Engineered FGF21 variant with enhanced therapeutic potential 1. Structure-based rational design (mutation-site patent granted) 2. Superior <i>in vitro</i> efficacy (vs. WT & comparator) 3. Superior <i>in vivo</i> efficacy in DIO & MASH mouse models (vs. WT & comparator) 4. Low risk of immunogenicity and toxicity 5. Ongoing development of long-acting FGF21M5-based fusion proteins
Development Stage	Lead
Route of Administration	Subcutaneous injection (SC)

Any unauthorized distribution or reproduction of this material is strictly prohibited.